Taiwan
· Delayed Price · Currency is TWD Pharmosa Biopharm Statistics
Total Valuation
Pharmosa Biopharm has a market cap or net worth of TWD 7.43 billion. The enterprise value is 5.94 billion.
| Market Cap | 7.43B |
| Enterprise Value | 5.94B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmosa Biopharm has 129.02 million shares outstanding. The number of shares has increased by 13.14% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 129.02M |
| Shares Change (YoY) | +13.14% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 8.58% |
| Owned by Institutions (%) | 3.03% |
| Float | 76.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 140.93 |
| PB Ratio | 3.89 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -20.28 |
| EV / Sales | 117.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.06 |
Financial Position
The company has a current ratio of 25.20, with a Debt / Equity ratio of 0.06.
| Current Ratio | 25.20 |
| Quick Ratio | 24.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -105.43 |
Financial Efficiency
Return on equity (ROE) is -18.71% and return on invested capital (ROIC) is -11.85%.
| Return on Equity (ROE) | -18.71% |
| Return on Assets (ROA) | -11.52% |
| Return on Capital (ROIC) | -11.85% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 2.10 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.80% in the last 52 weeks. The beta is 0.52, so Pharmosa Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -31.80% |
| 50-Day Moving Average | 63.36 |
| 200-Day Moving Average | 73.53 |
| Relative Strength Index (RSI) | 37.79 |
| Average Volume (20 Days) | 177,562 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmosa Biopharm had revenue of TWD 50.52 million and -292.93 million in losses. Loss per share was -2.37.
| Revenue | 50.52M |
| Gross Profit | 13.42M |
| Operating Income | -322.84M |
| Pretax Income | -292.93M |
| Net Income | -292.93M |
| EBITDA | -313.82M |
| EBIT | -322.84M |
| Loss Per Share | -2.37 |
Balance Sheet
The company has 1.61 billion in cash and 122.00 million in debt, giving a net cash position of 1.49 billion or 11.56 per share.
| Cash & Cash Equivalents | 1.61B |
| Total Debt | 122.00M |
| Net Cash | 1.49B |
| Net Cash Per Share | 11.56 |
| Equity (Book Value) | 1.90B |
| Book Value Per Share | 14.79 |
| Working Capital | 1.61B |
Cash Flow
In the last 12 months, operating cash flow was -265.57 million and capital expenditures -189.27 million, giving a free cash flow of -454.84 million.
| Operating Cash Flow | -265.57M |
| Capital Expenditures | -189.27M |
| Free Cash Flow | -454.84M |
| FCF Per Share | -3.53 |
Margins
| Gross Margin | 26.57% |
| Operating Margin | -639.02% |
| Pretax Margin | -579.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -900.31% |
Dividends & Yields
Pharmosa Biopharm does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.14% |
| Shareholder Yield | -13.14% |
| Earnings Yield | -4.12% |
| FCF Yield | -6.12% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |